L. Rollin

发表

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

D. Schadendorf, P. Ascierto, R. Dummer, 2017, The New England journal of medicine.

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Dirk Schadendorf, Reinhard Dummer, Paolo A Ascierto, 2015, The New England journal of medicine.

Abstract CT075: Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients with advanced melanoma (CheckMate 067)

D. Schadendorf, C. Horak, R. Dummer, 2017 .

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

G. Linette, C. Horak, J. Wolchok, 2015, The New England journal of medicine.

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial

D. Schadendorf, P. Ascierto, M. Smylie, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.

K. Blennow, H. Soares, H. Soininen, 2012, Archives of neurology.

Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).

D. Schadendorf, C. Horak, R. Dummer, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer

C. Garbe, G. Long, X. Zhao, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study

G. Sachs, R. Mcquade, T. Iwamoto, 2006, Journal of psychopharmacology.

A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder.

J. Calabrese, P. Keck, R. Mcquade, 2006, The Journal of clinical psychiatry.

Efficacy of aripiprazole adjunctive to lithium or valproate in the long‐term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double‐blind, randomized study

L. Rollin, Arif Khan, W. Carson, 2011, Bipolar disorders.

A comparison of two fixed doses of aripiprazole with placebo in acutely relapsed, hospitalized patients with bipolar disorder I (manic or mixed) in subpopulations (CN138-007)

E. Vieta, R. Mcquade, L. Rollin, 2010, European Neuropsychopharmacology.

Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511).

P. Ascierto, M. Smylie, I. Svane, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM).

D. Hafler, H. Friedman, D. Reardon, 2014 .

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial

D. Schadendorf, P. Ascierto, M. Smylie, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy

M. Thase, J. Nelson, R. Berman, 2012, International clinical psychopharmacology.